Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 May 29;10(5):e2703.
doi: 10.7759/cureus.2703.

Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy

Affiliations
Case Reports

Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy

Nikolai Klebanov et al. Cureus. .

Abstract

Intravesical therapy with Bacillus Calmette-Guérin (BCG) is a common and effective therapy for bladder carcinoma in situ. The risks associated with intravesical BCG therapy are significant and rare. Accurate diagnosis and prompt initiation of management significantly reduce the morbidity associated with these risks. Here, we discuss a case of BCG orchitis, a rare but treatable complication of intravesical BCG therapy. We present the case of a 55-year-old Puerto Rican incarcerated male who was diagnosed with high-grade Stage T1 urothelial carcinoma after presenting with hematuria, treated with transurethral resection of bladder tumor (TURBT), mitomycin, and intravesical BCG. He presented with left testicular pain and swelling after a failed course of ciprofloxacin with ultrasound findings characteristic of BCG orchitis. The patient received a combination therapy of levofloxacin, rifampin, isoniazid, and ethambutol, which resulted in symptom resolution. Combination therapy was initiated in this patient based on a high index of clinical suspicion, and in the absence of positive cultures. Competing diagnoses were considered and excluded based on the history, imaging findings, and observed response to therapy. As this is an uncommon diagnosis, and as routine infectious workup is often inconclusive, we emphasize that early anti-tuberculous treatment should be considered given a high degree of clinical suspicion based on history and patient presentation.

Keywords: bacillus calmette-guerin (bcg); bcg orchitis; bladder cancer; ethambutol; isoniazid; levofloxacin; rifampin; testicular ultrasound; tuberculosis; tuberculous orchitis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Diffuse hypoechogenicity and hypervascularity on scrotal ultrasound
A-B) Ultrasonographic images of the left testis showing heterogeneous echogenicity with multiple patches of hypoechoic spots distributed throughout the testicle. C-D) Ultrasound with Doppler demonstrating marked hypervascularity of the left-sided structures. Patient also had a significant hydrocele surrounding the testicle.

References

    1. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Ritz N, Tebruegge M, Connell TG, et al. Antimicrob Agents Chemother. 2009;53:316–318. - PMC - PubMed
    1. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. Chang SS, Boorjian SA, Chou R, et al. J Urol. 2016;196:1021–1029. - PubMed
    1. Guidelines on bladder cancer. Oosterlinck W, Lobel B, Jakse G, et al. Eur Urol. 2002;41:105–112. - PubMed
    1. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Lamm DL. Clin Infect Dis. 2000;31:0. - PubMed
    1. Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al. Medicine (Baltimore) 2014;93:236–254. - PMC - PubMed

Publication types

LinkOut - more resources